Advertisement

European Cytokine Network

, Volume 27, Issue 4, pp 90–96 | Cite as

Plasma cytokine profiling to predict susceptibility to acute mountain sickness

  • Hui Lu
  • Rong Wang
  • Wenbin Li
  • Hua Xie
  • Chang Wang
  • Ying Hao
  • Yuhuan Sun
  • Zhengping Jia
Research Article
  • 20 Downloads

Abstract

Extensive studies have been performed on acute mountain sickness (AMS), but biomarkers predicting AMS are lacking. Presently, the mainstay methods to identify AMS biomarkers include proteomic and genetic methods at high altitudes or in hypoxic simulated chambers. In the present study, we compared plasma cytokine profiles between AMS-susceptible individuals and AMS-resistant individuals at low altitude by cytokine array analysis. In total, 75 differentially expressed cytokines were identified between AMS-susceptible individuals and AMS-resistant individuals, most involved in inflammation. A quantifiable human custom cytokine antibody array was then used to further test results of cytokine array analysis. Compared to AMS-resistant individuals, the level of insulin-like growth factor binding protein 6 (IGFBP-6) was significantly lower in AMS-susceptible individuals (37,318.99 ± 23,493.11 pg/mL and 25,665.38 ± 25,691.29 pg/mL, respectively; P = 0.04). Conversely, the levels of serum amyloid A1 (SAA1), dickkopf WNT signaling pathway inhibitor 4 (Dkk4), and interleukin 17 receptor A (IL-17RA) were significantly higher in AMS-susceptible individuals than in AMS-resistant individuals (SAA1: 4,069.69 ± 2,502.93 pg/mL vs. 2,994.98 ± 2,295.91 pg/mL, P = 0.05; Dkk4: 2,090.00 ± 2,094.89 pg/mL vs. 1,049.88 ± 1,690.93 pg/mL, P = 0.07; IL-17RA: 11.52 ± 8.33 pg/mL vs. 8.67 ± 6.22 pg/mL, P = 0.08). Although further in-depth research is required to examine the possible role of these cytokines in the development of AMS, these four cytokines may be of use in predicting AMS-susceptibility in a low-altitude environment.

Key words

cytokines biomarkers acute mountain sickness nonaltitude environment Chinese 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    West JB, American College of P. JB, American Physiological S. JB. The physiologic basis of high-altitude diseases. Ann Intern Med 2004; 141: 789–800.CrossRefPubMedGoogle Scholar
  2. 2.
    Bartsch P, Swenson ER. Clinical practice: acute high-altitude illnesses. N Engl J Med 2013; 368: 2294–302.CrossRefPubMedGoogle Scholar
  3. 3.
    Kayser B, Dumont L, Lysakowski C, Combescure C, Haller G, Tramer MR. Reappraisal of acetazolamide for the prevention of acute mountain sickness: a systematic review and meta-analysis. High Alt Med Biol 2012; 13: 82–92.CrossRefPubMedGoogle Scholar
  4. 4.
    Tang E, Chen Y, Luo Y. Dexamethasone for the prevention of acute mountain sickness: systematic review and meta-analysis. Int J Cardiol 2014; 173: 133–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Dumont L, Mardirosoff C, Tramer MR. Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review. BMJ 2000; 321: 267–72.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Ellsworth AJ, Larson EB, Strickland D. Arandomized trial of dexamethasone and acetazolamide for acute mountain sickness prophylaxis. Am J Med 1987; 83: 1024–30.CrossRefPubMedGoogle Scholar
  7. 7.
    Subedi BH, Pokharel J, Goodman TL, et al. Complications of steroid use on Mt. Everest. Wilderness Environ Med 2010; 21: 345–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Julian CG, Subudhi AW, Hill RC, et al. Exploratory proteomic analysis of hypobaric hypoxia and acute mountain sickness in humans. J Appl Physiol 2014; 116: 937–44 (1985).CrossRefPubMedGoogle Scholar
  9. 9.
    MacInnis MJ, Koehle MS, Rupert JL. Evidence for a genetic basis for altitude illness: 2010 update. High Alt Med Biol 2010; 11: 349–68.CrossRefPubMedGoogle Scholar
  10. 10.
    Julian CG, Subudhi AW, Wilson MJ, Dimmen AC, Pecha T, Roach RC. Acute mountain sickness, inflammation, and permeability: new insights from a blood biomarker study. J Appl Physiol 2011; 111: 392–9 (1985).CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Chiu TF, Chen LL, Su DH, et al. Rhodiola crenulata extract for prevention of acute mountain sickness: a randomized, double-blind, placebo-controlled, crossover trial. BMC Complement Altern Med 2013; 13: 298.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Roach RC, Maes D, Sandoval D, et al. Exercise exacerbates acute mountain sickness at simulated high altitude. J Appl Physiol 2000; 88: 581–5 (1985).PubMedGoogle Scholar
  13. 13.
    Rink C, Khanna S. Significance of brain tissue oxygenation and the arachidonic acid cascade in stroke. Antioxid Redox Signal 2011; 14: 1889–903.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248–54.CrossRefPubMedGoogle Scholar
  15. 15.
    Zor T, Selinger Z. Linearization of the Bradford protein assay increases its sensitivity: theoretical and experimental studies. Anal Biochem 1996; 236: 302–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Hackett PH, Roach RC. High-altitude illness. N Engl J Med 2001; 345: 107–14.CrossRefPubMedGoogle Scholar
  17. 17.
    Hartmann G, Tschop M, Fischer R, et al. High altitude increases circulating interleukin-6, interleukin-1 receptor antagonist and C-reactive protein. Cytokine 2000; 12: 246–52.CrossRefPubMedGoogle Scholar
  18. 18.
    Van Osta A, Moraine JJ, Melot C, Mairbaurl H, Maggiorini M, Naeije R. Effects of high altitude exposure on cerebral hemodynamics in normal subjects. Stroke 2005; 36: 557–60.CrossRefPubMedGoogle Scholar
  19. 19.
    Song H, Ke T, Luo WJ, Chen JY. Non-high altitude methods for rapid screening of susceptibility to acute mountain sickness. BMC Public Health 2013; 13: 902.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Xu S, Cao X. Interleukin-17 and its expanding biological functions. Cell Mol Immunol 2010; 7: 164–74.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Bruning U, Fitzpatrick SF, Frank T, Birtwistle M, Taylor CT, Cheong A. NFkappaB and HIF display synergistic behaviour during hypoxic inflammation. Cell Mol Life Sci 2012; 69: 1319–29.CrossRefPubMedGoogle Scholar
  22. 22.
    Petousi N, Croft QP, Cavalleri GL, et al. Tibetans living at sea level have a hyporesponsive hypoxia-inducible factor system and blunted physiological responses to hypoxia. J Appl Physiol 2014; 116: 893–904 (1985).CrossRefPubMedGoogle Scholar
  23. 23.
    Kebir H, Kreymborg K, Ifergan I, et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 2007; 13: 1173–5.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Huppert J, Closhen D, Croxford A, et al. Cellular mechanisms of IL-17-induced blood-brain barrier disruption. FASEB J 2010; 24: 1023–34.CrossRefPubMedGoogle Scholar
  25. 25.
    Huber JD, Egleton RD, Davis TP. Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. Trends Neurosci 2001; 24: 719–25.CrossRefPubMedGoogle Scholar
  26. 26.
    Diz AP, Truebano M, Skibinski DO. The consequences of sample pooling in proteomics: an empirical study. Electrophoresis 2009; 30: 2967–75.CrossRefPubMedGoogle Scholar
  27. 27.
    Karp NA, Lilley KS. Investigating sample pooling strategies for DIGE experiments to address biological variability. Proteomics 2009; 9: 388–97.CrossRefPubMedGoogle Scholar

Copyright information

© John Libbey Eurotext 2016

Authors and Affiliations

  1. 1.Key Laboratory of the plateau of environmental damage controlLanzhou General Hospital of Lanzhou Military CommandLanzhouChina
  2. 2.Key Laboratory of the plateau of environmental damage controlLanzhou General Hospital of Lanzhou Military CommandLanzhouChina

Personalised recommendations